tradingkey.logo
tradingkey.logo
Search

Collegium Pharmaceutical Inc

COLL
Add to Watchlist
35.390USD
-0.590-1.64%
Close 07-31 16:00ETQuotes delayed by 15 min
1.15BMarket Cap
15.00P/E TTM

Earnings Forecast

Currency: USD Updated: 2026-07-31
Previous score
8.00
Change
0
The current earnings forecast score of Collegium Pharmaceutical Inc is 8.00, ranking 56 out of 155 in the Pharmaceuticals industry. The average price target is 48.00, with a high of 58.00 and a low of 44.00.

Analyst Rating

Based on 6 analysts
Buy
Current Rating
54.333
Target Price
+53.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Collegium Pharmaceutical Inc
COLL
6
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Forecast
Actual

FAQs

What is Collegium Pharmaceutical Inc's expected revenue for the next quarter?

Collegium Pharmaceutical Inc's expected revenue is 201.21M.

What is Collegium Pharmaceutical Inc's price target?

Analysts forecast that Collegium Pharmaceutical Inc's price target is USD 48.00, with the highest forecast at USD 58.00 and the lowest forecast at USD 44.00.

How have Collegium Pharmaceutical IncCOLL's recent earnings per share performed?

The market expectation was USD 0.45, while Collegium Pharmaceutical IncCOLL's earnings per share (EPS) for the previous quarter was USD 0.54. EPS for the next quarter is expected at USD 1.72.

What is the analyst rating for Collegium Pharmaceutical Inc?

Based on the ratings of Collegium Pharmaceutical Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.